Interim results Q2-2011 for Biotec Pharmacon

Highlights:
 
ENZYMES - ArcticZymes
 
  * Revenue affected by low deliveries of the lead product SAP to our exclusive
    customer and distributor Affymetrix (USB)
  * Good growth for the other products
  * Signed new multiproduct contracts with PrimerDesign and TATAA Biocenter,
    both exposing the ArcticZymes brand name
 
BETA-GLUCANS
 
  * Good sales growth for beta-glucan bulk products to the dietary supplement
    market
  * Third animal study confirms that a SBG hydrogel formulation has
    statistically significant better wound healing capabilities than a
    commercially available active hydrogel
  * Suitable packaging container (tube) identified for the first generation SBG
    hydrogel - formal stability study ongoing
  * Obtained registration of Woulgan® as intended trade name for the first
    generation hydrogel
  * Commercial partnering process continuing. The opportunity of a more
     advanced regulatory positioning (Class III device) is expected to make the
    process more time-consuming, without slowing down the actual product
    development process
 
FINANCIAL DEVELOPMENT AND POSITION
 
  * Improvement in pre-tax result by NOK 10.4 million to NOK -8.2 million in
    first half of 2011, although with only small year-on-year improvement in the
    second quarter
  * Cash balance of NOK 42 million per 30 June, 2011
 
OUTLOOK
 
  * Enzymes: Temporary lower sales expected for SAP - ArcticZymes is working to
    resume control over the situation. Good growth expected for other products
  * Beta-Glucans: Product development and partnering processes moving on in
    concert
 
Please find attached the full interim report for the second quarter and first
half year 2011.
 
For further information, please contact:
 
Svein W. F. Lien - CEO:   +47 922 89 323
 
The company hosts a presentation of the interim results on August 10th at 08:00
at Thon Conference, Vika Atrium, Oslo.
 
The presentation will also be available as webcast with log on atwww.biotec.no.
 
This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
 
Interim_Report_Q2_2011: 
http://hugin.info/136141/R/1537197/469146.pdf
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: Biotec Pharmacon ASA via Thomson Reuters ONE
 
[HUG#1537197]